Cardiovascular & hematological disorders drug targets最新文献_第7页

Factors which influence the levels of ST-2, Galectin-3 and MMP-9 in Acute Coronary Syndrome. 急性冠脉综合征患者ST-2、半乳糖凝集素-3和MMP-9水平的影响因素

Cardiovascular & hematological disorders drug targets Pub Date : 2019-01-01 DOI: 10.2174/1871529X19666190719104005

L. Goenka, D. Jha, M. Sharma, V. Dhandapani, M. George

{"title":"Factors which influence the levels of ST-2, Galectin-3 and MMP-9 in Acute Coronary Syndrome.","authors":"L. Goenka, D. Jha, M. Sharma, V. Dhandapani, M. George","doi":"10.2174/1871529X19666190719104005","DOIUrl":"https://doi.org/10.2174/1871529X19666190719104005","url":null,"abstract":"BACKGROUND Several cardiac biomarkers are being studied to explore their potential in the prognostication of Acute Coronary Syndrome (ACS). However, there are limited studies exploring the relationship between these biomarkers and clinical, laboratory and demographic characteristics. OBJECTIVE We sought to characterize Galectin-3, ST-2 and Matrix metallopeptidase 9 (MMP-9), and their association with routine clinical, laboratory and demographic parameters and how these parameters can influence their levels in ACS patients. METHODS A total of 122 patients with ACS were enrolled in the study. The study patients were categorized into two groups namely: STEMI (n=58) and NSTEMI/UA (n=64). Plasma samples were used to determine the level of biomarkers, Galectin-3 and ST-2, and serum samples were used to determine the levels of MMP-9 using the Enzyme-linked immunosorbent assay (ELISA). The association between the plasma and serum levels of biomarkers and, demographic, clinical and laboratory variables were determined. Statistical analyses for the study were performed using SPSS 16.0 software (SPSS Inc., Chicago, IL, USA). RESULTS Elderly aged [0.107 (0.012-0.969); p=0.047] patients had higher ST-2. Galectin-3 was higher among female patients [3.693(1.253-10.887); p=0.018] and patients with low left ventricular ejection fraction [2.882 (1.041-7.978); p=0.042]. Patients with lower body mass index [3.385 (1.241-9.231); p=0.017], diabetes [3.650 (1.302-10.237); p=0.014] and high total leukocyte count [2.900 (1.114-7.551; p=0.029] had higher MMP-9 levels. CONCLUSION High Galectin-3, MMP-9, and ST-2 are independently influenced to a certain degree by demographic, clinical and laboratory characteristics. However, no single characteristic was found to be commonly associated with all of the three biomarkers.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":"116 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77812886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Exogenous Factors from Venomous and Hematophagous Animals in Drugs and Diagnostic Developments for Cardiovascular and Neurovascular Diseases. 心血管和神经血管疾病药物和诊断发展中的毒液和食血动物外源因子。

Cardiovascular & hematological disorders drug targets Pub Date : 2019-01-01 DOI: 10.2174/1871529X1902190619123603

Cho Yeow Koh, R. Kini

引用次数: 1

Impact of Leukemia Stem Cells Phenotype Expression on Response to Induction Therapy in Acute Myeloid Leukemia Patients. 白血病干细胞表型表达对急性髓系白血病诱导治疗应答的影响。

Cardiovascular & hematological disorders drug targets Pub Date : 2019-01-01 DOI: 10.2174/1871529X19666190719105954

F. Almohsen, S. Al-Mudallal

{"title":"Impact of Leukemia Stem Cells Phenotype Expression on Response to Induction Therapy in Acute Myeloid Leukemia Patients.","authors":"F. Almohsen, S. Al-Mudallal","doi":"10.2174/1871529X19666190719105954","DOIUrl":"https://doi.org/10.2174/1871529X19666190719105954","url":null,"abstract":"BACKGROUND Laboratory data suggest that acute myeloid leukemia AML originates from a rare population of cells, termed leukemic stem cells (LSCs) or leukemia-initiating cells, which are capable of self-renewal, proliferation and differentiation into malignant blasts. There's a universal agreement that LSCs lie within the CD34+ compartment of hemopoietic cells and most of leukemic stem cells express the interleukin-3 alpha chain receptor, CD123 and lack CD38 . This study aimed to estimate the expression of LSC phenotype in AML patients and to correlate it with response to induction therapy. METHODS A cohort of 41 patients older than 15 years with newly diagnosed de novo AML were enrolled in this study. They were obtained from the National center of hematology in Baghdad and Baghdad teaching hospital between February and July 2013. The expression of CD34, CD38 and CD123 was assessed by multi-color flow cytometry. LSC positive (LSC+) samples must express CD34 and CD123 and lack the expression of CD38 in >1% of cells. French American British (FAB) classification system was used in this study. After four weeks of induction therapy; three groups were found: those who reached the complete morphological remission (CR), those who failed to reach CR and those who died before assessment of morphological remission. The last two groups were merged for statistical purposes. RESULTS After the course of induction therapy, 41.46% of patients had complete morphological remission while 58.54% of the studied patients failed to reach complete remission. The complete remission (CR) rate was higher (53.33%) in patients who were negative for LSC phenotype than patients who were positive for LSC phenotype (34.61%). CONCLUSIONS 1. LSCs were expressed in 63.41% of AML cases and were distributed among FAB subtypes without preference to any FAB subtype. 2. The expression of LSC phenotype was associated with poor response to induction therapy in AML patients.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87478210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Meet Our Associate Editor 认识我们的副主编

Cardiovascular & hematological disorders drug targets Pub Date : 2018-10-01 DOI: 10.2174/1871529X1803181001165640

P. Ferroni

引用次数: 0

Meet Our Editorial Board Member 见见我们的编辑委员会成员

Cardiovascular & hematological disorders drug targets Pub Date : 2018-06-28 DOI: 10.2174/1871529x1802180628114324

G. Aliev

引用次数: 0

Connexin43 and Myocardial Ischemia-Reperfusion Injury. Connexin43与心肌缺血再灌注损伤。

Cardiovascular & hematological disorders drug targets Pub Date : 2018-01-01 DOI: 10.2174/1871529X16666161227143644

L. Zu, N. Wen, Changjie Liu, Mingming Zhao, Lemin Zheng

{"title":"Connexin43 and Myocardial Ischemia-Reperfusion Injury.","authors":"L. Zu, N. Wen, Changjie Liu, Mingming Zhao, Lemin Zheng","doi":"10.2174/1871529X16666161227143644","DOIUrl":"https://doi.org/10.2174/1871529X16666161227143644","url":null,"abstract":"BACKGROUND Recently, the treatment and prevention of ischemic cardiomyopathy is one of the emerging research topics in the cardiovascular field. Gap junction is the basic structure of cardiac electrophysiology. Connexin is the basic unit of gap junctions. Connexin43(CX43) is the most abundant member of Cx family in the heart, the normal expression of Cx43 is important for heart development, electrically coupled cardiomyocytes activities and coordination of myocardial function. The connection between Cx43 and myocardial ischemia/reperfusion or reperfusion injury has become the focus of current research. METHODS We undertook a structured search of bibliographic database for peer-reviewed research literature using a focused review question and inclusion/exclusion criteria. The quality of retrieved papers was appraised using standard tools. The characteristics of screened papers were described, and a deductive qualitative content analysis methodology was applied to analyze the interventions and findings of included studies using a conceptual framework. RESULTS Twenty-one papers were included in the review, eight papers outlined the relationship of Cx43 and reperfusion arrhythmias. Eight papers pointed out the effect on the infarct size of Cx43. CONCLUSION The findings of this review confirm that Cx43 is the most abundant member of Cx family in the heart and is vital for myocardial protection during ischemia/reperfusion process and for ischemia/reperfusion injury. Many of its mechanism are still not very clear and require future research in the future.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":"15 1","pages":"14-16"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82989464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Should Arterial Embolization in Recurrent Spontaneous Hemoph ilic Hemarthroses Refractory to Intensive Prophylaxis be the First Invasive Resort? 动脉栓塞治疗难治性复发性自发性血肿是否应该是首选侵入性治疗手段?

Cardiovascular & hematological disorders drug targets Pub Date : 2017-07-04 DOI: 10.2174/1871529X17666161216112745

E. Rodríguez‐Merchán

{"title":"Should Arterial Embolization in Recurrent Spontaneous Hemoph ilic Hemarthroses Refractory to Intensive Prophylaxis be the First Invasive Resort?","authors":"E. Rodríguez‐Merchán","doi":"10.2174/1871529X17666161216112745","DOIUrl":"https://doi.org/10.2174/1871529X17666161216112745","url":null,"abstract":"BACKGROUND\u0000Some reports have suggested that arterial embolization (AE) is a good indication to manage recurrent spontaneous hemartroses (RSH) that are refractory to intensive prophylaxis (RIP) in people with hemophilia (PWH).\u0000\u0000\u0000OBJECTIVE\u0000To clarify the role of AE in RSH that are RIP in PWH.\u0000\u0000\u0000METHOD\u0000A literature review of arterial embolization in patients with hemophilia was performed using MEDLINE (PubMed) and the Cochrane Library.\u0000\u0000\u0000RESULTS\u0000A total of 68 articles were found, of which 6 were selected and reviewed because they were deeply focused on the topic. The total number of AEs performed so far is 78 in 69 patients. Four second AEs were required (4/78), and a third AE in one (1/78). Two complications have been found so far: a pseudoaneurym (1/78) of the femoral artery at the puncture site (that eventually required surgical repair) and a patient (1/78) that had recurrence of bleeding for whom surgical exploration was required. AE seems to be a good procedure for RSH that are RIP.\u0000\u0000\u0000CONCLUSION\u0000AE seems to be too aggressive to be considered the first resort. Radiosynovectomy (RS) must always be the first resort. AE should only be indicated in RSH that are RIP to 3 RSs (with 6 month intervals) followed by an arthroscopic synovectomy. AE in PWH is technically challenging and should be performed by highly skilled interventional radiologists.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":"25 1","pages":"33-37"},"PeriodicalIF":0.0,"publicationDate":"2017-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83017320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of the Acute Hematopoietic Capacities of Erythropoietin and U-74389G Concerning Hematocrit Levels. 促红细胞生成素与U-74389G急性造血能力与红细胞压积水平的比较

Cardiovascular & hematological disorders drug targets Pub Date : 2017-07-04 DOI: 10.2174/1871529X17666170201104158

C. Tsompos, C. Panoulis, K. Toutouzas, A. Triantafyllou, G. Zografos, A. Papalois

{"title":"Comparison of the Acute Hematopoietic Capacities of Erythropoietin and U-74389G Concerning Hematocrit Levels.","authors":"C. Tsompos, C. Panoulis, K. Toutouzas, A. Triantafyllou, G. Zografos, A. Papalois","doi":"10.2174/1871529X17666170201104158","DOIUrl":"https://doi.org/10.2174/1871529X17666170201104158","url":null,"abstract":"AIM\u0000This study compared the hematopoietic capacities of erythropoietin (Epo) and antioxidant drug U-74389G, based on 2 preliminary studies. The provided results on hematocrit levels augmentation were co-evaluated in a hypoxia reoxygenation protocol of an animal model.\u0000\u0000\u0000MATERIALS AND METHODS\u0000Hematocrit levels were evaluated at the 60th reoxygenation min (for groups A, C and E) and at the 120th reoxygenation min (for groups B, D and F) in 60 rats. Groups A and B received no drugs, rats from groups C and D were administered with Epo; whereas rats from groups E and F were administered with U-74389G.\u0000\u0000\u0000RESULTS\u0000The first preliminary study of Epo non-significantly increased the hematocrit levels by 0.24%+1.38% (p-value=0.8586). The second preliminary study of U-74389G significantly raised the hematocrit levels by 3.16%+1.33% (p-value=0.0196). These 2 studies were co-evaluated since they came from the same experimental setting. The outcome of the co-evaluation was that U-74389G has approximately 12.66-fold higher hematopoietic potency than Epo (p-value=0.0000).\u0000\u0000\u0000CONCLUSION\u0000The anti-oxidant capacities of U-74389G provide satisfactory acute hematopoietic properties; presenting approximately 12.66-fold hematocrit level rise than epo (p-value=0.0000).","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":"78 1","pages":"24-27"},"PeriodicalIF":0.0,"publicationDate":"2017-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72854676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Biomarker Assays for Personalised Stroke Risk Assessment in Atrial Fibrillation. 房颤个体化卒中风险评估的生物标志物分析。

Cardiovascular & hematological disorders drug targets Pub Date : 2017-03-31 DOI: 10.2174/1871529X17666170104120746

A. Hall, Rupert Simpson, A. Mitchell

{"title":"Biomarker Assays for Personalised Stroke Risk Assessment in Atrial Fibrillation.","authors":"A. Hall, Rupert Simpson, A. Mitchell","doi":"10.2174/1871529X17666170104120746","DOIUrl":"https://doi.org/10.2174/1871529X17666170104120746","url":null,"abstract":"BACKGROUND\u0000Atrial fibrillation is a well-known independent risk factor for stroke yet there is no international consensus on guidelines regarding the introduction of anticoagulation in patients deemed at intermediate risk (e.g. CHA2DS2-VASc of 1). The evolution of cardiac biomarkers such as highly sensitive troponins and B-type natriuretic peptide as well as data on D-dimers, may offer incremental enhancements for personalized thromboembolism risk assessment. These markers provide prognostic data for risk of cardiovascular morbidities associated with atrial fibrillation and offer additional specificity for assessing stroke and thromboembolic risk. These assays may therefore enhance risk prognosis in atrial fibrillation alongside conventional stroke risk stratification tool patients. We seek to explore the application of personalised risk assessment using the biomarkers to aid the clinician treating the patient with atrial fibrillation deemed to be at intermediate risk of stroke.\u0000\u0000\u0000CONCLUSION\u0000The stroke risk assessment of a patient with an intermediate risk of stroke (CHA2DS2- VASc score 1) may be improved by using cardiac biomarkers such as highly sensitive troponin, BNP and D-dimers. We explore the application of these biomarkers to provide personalised risk assessment to help a patient with AF decide on whether to commence anticoagulation.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":"11 1","pages":"58-63"},"PeriodicalIF":0.0,"publicationDate":"2017-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89269988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Evaluation of Antidiabetic Activity of Carnosol (Phenolic Diterpene in Rosemary) in Streptozotocin-Induced Diabetic Rats. 迷迭香酚(迷迭香酚二萜)对链脲佐菌素诱导的糖尿病大鼠抗糖尿病活性的评价。

Cardiovascular & hematological disorders drug targets Pub Date : 2017-03-31 DOI: 10.2174/1871529X16666161229154910

S. Samarghandian, A. Borji, T. Farkhondeh

{"title":"Evaluation of Antidiabetic Activity of Carnosol (Phenolic Diterpene in Rosemary) in Streptozotocin-Induced Diabetic Rats.","authors":"S. Samarghandian, A. Borji, T. Farkhondeh","doi":"10.2174/1871529X16666161229154910","DOIUrl":"https://doi.org/10.2174/1871529X16666161229154910","url":null,"abstract":"BACKGROUND\u0000Carnosol (CS) is an ortho-diphenolic diterpene in rosemary with great antioxidant potential. This study was designed to investigate the hypolipidemic, anti-oxidant, and anti-diabetic activities of CS.\u0000\u0000\u0000METHODS\u0000In our experiment, the rats were divided into the following groups of 8 animals each: control, untreated diabetic, three CS (1, 5, 10 mg/kg/day)-treated diabetic groups. On the first day of the study, the diabetic groups were given streptozotocin (STZ) in a single intraperitoneal (i.p.) injection at a dose of 60 mg/kg for induction of diabetes. CS was injected (i.p.) to the treatment groups from 3 days after STZ administration during a period of 4 weeks. At the end of the experimental period, we assessed the serum levels of glucose, IL-6, TNF-α, malondialdehyde (MDA), glutathione-s transferase (GST), superoxide dismutase (SOD), catalase (CAT) activities, triglycerides (TG), total cholesterol (TC), low density lipoprotein (LDL-C), and high density lipoprotein (HDL-C).\u0000\u0000\u0000RESULTS\u0000The results indicated that STZ caused an elevation of serum glucose, IL-6, TNF-α, MDA, TG, TC, LDL-C, and it also made a reduction of serum GST, SOD, CAT, and HDL-C (p<0.001). The findings showed amelioration in the serum glucose, IL-6, TNF-α, MDA, TG, TC, LDL-C, GST, SOD, CAT, and HDL-C in the CS-treated diabetic groups versus the untreated group, in a dose dependent manner (p < 0.001).\u0000\u0000\u0000CONCLUSION\u0000In conclusion, the present investigation proposes that CS may be improved diabetes and its complications by modulation of oxidative stress and inflammatory responses.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":"6 1","pages":"11-17"},"PeriodicalIF":0.0,"publicationDate":"2017-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91232331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 28